C Frank Bennett

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2340677/publications.pdf

Version: 2024-02-01

39	12,823	87888 38	315739 38
papers	citations	h-index	g-index

39	39	39	10930
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antisense Drugs Make Sense for Neurological Diseases. Annual Review of Pharmacology and Toxicology, 2021, 61, 831-852.	9.4	54
2	Î±-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinsonâ€™s disease. JCI Insight, 2021, 6, .	5.0	60
3	Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS. Science Translational Medicine, 2021, 13, .	12.4	68
4	Cholesterol-functionalized DNA/RNA heteroduplexes cross the bloodâ€“brain barrier and knock down genes in the rodent CNS. Nature Biotechnology, 2021, 39, 1529-1536.	17.5	75
5	Phase 1â€“2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 2020, 383, 109-119.	27.0	354
6	Antisense oligonucleotide drugs for neurological and neuromuscular disease. , 2020, , 221-245.		0
7	Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. Annual Review of Neuroscience, 2019, 42, 385-406.	10.7	214
8	Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates. Nucleic Acids Research, 2019, 47, 6045-6058.	14.5	48
9	Targeting Huntingtin Expression in Patients with Huntingtonâ€™s Disease. New England Journal of Medicine, 2019, 380, 2307-2316.	27.0	493
10	Nusinersen in later-onset spinal muscular atrophy. Neurology, 2019, 92, e2492-e2506.	1.1	183
11	Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nature Neuroscience, 2019, 22, 180-190.	14.8	345
12	Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. New England Journal of Medicine, 2018, 378, 625-635.	27.0	977
13	Huntingtin suppression restores cognitive function in a mouse model of Huntingtonâ€™s disease. Science Translational Medicine, 2018, 10, .	12.4	89
14	Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7. Science Translational Medicine, 2018, 10, .	12.4	63
15	Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. Journal of Clinical Investigation, 2018, 128, 3558-3567.	8.2	171
16	Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Science Translational Medicine, 2017, 9, .	12.4	354
17	Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature, 2017, 544, 362-366.	27.8	263
18	Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice. Molecular Therapy - Nucleic Acids, 2017, 7, 465-474.	5.1	71

#	Article	IF	Citations
19	Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. New England Journal of Medicine, 2017, 377, 1723-1732.	27.0	1,533
20	Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet, The, 2016, 388, 3017-3026.	13.7	801
21	Results from a phase 1 study of nusinersen (ISIS-SMN _{Rx}) in children with spinal muscular atrophy. Neurology, 2016, 86, 890-897.	1.1	506
22	DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nature Communications, 2015, 6, 7969.	12.8	99
23	Identification and Characterization of Modified Antisense Oligonucleotides Targeting DMPK in Mice and Nonhuman Primates for the Treatment of Myotonic Dystrophy Type 1. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 329-340.	2.5	106
24	Pharmacology of a Central Nervous System Delivered 2â€²-O-Methoxyethylâ€“Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 46-55.	2.5	238
25	Antisense Oligonucleotide-Based Therapies for Diseases Caused by pre-mRNA Processing Defects. Advances in Experimental Medicine and Biology, 2014, 825, 303-352.	1.6	60
26	Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients. PLoS ONE, 2014, 9, e107434.	2.5	92
27	An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurology, The, 2013, 12, 435-442.	10.2	534
28	RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention. Neuron, 2013, 80, 415-428.	8.1	785
29	Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Research, 2013, 41, 9634-9650.	14.5	138
30	Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4530-9.	7.1	508
31	Antisense Oligonucleotide-Mediated Correction of Transcriptional Dysregulation is Correlated with Behavioral Benefits in the YAC128 Mouse Model of Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 217-228.	1.9	58
32	Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis. Neuron, 2012, 74, 1031-1044.	8.1	635
33	Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends in Molecular Medicine, 2012, 18, 634-643.	6.7	116
34	Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene / Allele-Specific Silencing of Mutant Huntingtin. Molecular Therapy, 2011, 19, 2178-2185.	8.2	246
35	Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy. Science Translational Medicine, 2011, 3, 72ra18.	12.4	437
36	Allele-Selective Inhibition of Mutant Huntingtin Expression with Antisense Oligonucleotides Targeting the Expanded CAG Repeat. Biochemistry, 2010, 49, 10166-10178.	2.5	127

#	Article	IF	Citations
37	RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform. Annual Review of Pharmacology and Toxicology, 2010, 50, 259-293.	9.4	1,136
38	Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Research, 2007, 35, 687-700.	14.5	361
39	Antisense oligonucleotide therapy for neurodegenerative disease. Journal of Clinical Investigation, 2006, 116, 2290-2296.	8.2	425